Activation of AXL kinase has been associated with acquired resistance to EGFR kinase inhibitors in EGFR mutant lung cancer, with evidence for epithelial-to-mesenchymal transition in preclinical models and restored EGFR kinase inhibitor sensitivity upon AXL inhibition [15, 16]. This evidence concerns the gene EGFR and lung carcinoma.